Q4 2026
Ends Dec 30, 2026
Revenue
$0.0B
$0.0B to $0.0B
EPS
-1.17
-1.17 to -1.17
No analyst count
EPS: No analyst count
May 3, 10:15 PM UTC
stable/analyst-estimates
Healthcare
Live Price
Offline$54.65
+0.00% today
Window Change
+1.15%
Window
Jun 23, 2025 → Dec 9, 2025
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 119 bars · Jun 23, 2025 → Dec 9, 2025
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Akero Therapeutics, Inc. (AKRO) is a Healthcare stock with a market cap of $4.50B. The stock last traded around $54.65 and up 1.1% across the available one-year price window (Jun 23, 2025 → Dec 9, 2025). Baseline metrics include revenue growth of 0.0%, EPS growth of -29.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -29.8%, free cash flow -59.0% with operating margin 0.0% and ROIC -34.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines AKRO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
AKRO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
AKRO Max Drawdown
-25.05%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for AKRO and SPY.
EPS Consensus
-1.17
Range -1.17 → -1.17
No analyst count
vs prior: -6.6%Revenue Outlook
$0.0B
Range $0.0B → $0.0B
No analyst count
Consensus Spread
Lower spread suggests tighter agreement across covering analysts.
Trend
Consensus average across visible periods
Trend
Average analyst revenue estimate
Timeline
Sorted by period end date. Includes both cached rows and live fallbacks from FMP.
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.